

Resource Summary Report

Generated by T1D on Jul 31, 2026

PathSeq

RRID:SCR_005203

Type: Tool

Proper Citation

PathSeq (RRID:SCR_005203)

Resource Information

URL: <http://www.broadinstitute.org/software/pathseq/>

Proper Citation: PathSeq (RRID:SCR_005203)

Description: A computational tool for the identification and analysis of microbial sequences in high-throughput human sequencing data that is designed to work with large numbers of sequencing reads in a scalable manner. This process is composed of a subtractive phase in which input reads are subtracted by alignment to human reference sequences, and an analytic phase in which the remaining reads are aligned to microbial reference sequences (viral, fungal, bacterial, archaeal) and de novo assembled. PathSeq is currently available in a cloud computing environment via Amazon Web Services. The typical approach one would take to pathogen discovery with PathSeq: RNA or DNA is extracted from the tissue of interest and sequencing libraries are constructed to be run on the next-generation DNA sequencing platform of choice. The resulting sequence data is run through the PathSeq pipeline in a cloud computing environment. PathSeq reports potential microbes in the sequence data as well as the complete set of reads that could not be identified as human or microbial sequences.

Abbreviations: PathSeq

Synonyms: PathSeq: Pathogen Discovery

Resource Type: software resource

Defining Citation: [PMID:21552235](#)

Keywords: virus, microbe, pathogen, dna, rna, next-generation sequencing

Availability: Acknowledgement requested, Account required, (for Amazon Web Services and you will need to pay for the AWS resource time)

Resource Name: PathSeq

Resource ID: SCR_005203

Alternate IDs: OMICS_00221

Record Creation Time: 20220129T080228+0000

Record Last Update: 20260725T190600+0000

Ratings and Alerts

No rating or validation information has been found for PathSeq.

No alerts have been found for PathSeq.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 62 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Aggarwal N, et al. (2025) Insights into expression and localization of HPV16 LCR-associated transcription factors and association with LCR activity in HNSCC. Molecular therapy. Oncology, 33(1), 200926.

Karta J, et al. (2025) Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer. The EMBO journal, 44(19), 5375.

Sheehan DH, et al. (2025) Altered Bacteria Abundance Is Associated With Outcomes in Head and Neck Squamous Cell Carcinoma. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 173(2), 420.

Hajjar J, et al. (2025) Gut dysbiosis patterns in CVID patients with noninfectious complications observed in a germ-free mouse model through fecal microbiota transplantation. Journal of human immunity, 1(1).

Shitara K, et al. (2025) Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Nature medicine, 31(5), 1519.

Booth ME, et al. (2025) The relationship between the gastric cancer microbiome and clinicopathological factors: a metagenomic investigation from the 100,000 genomes project and The Cancer Genome Atlas. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 28(3), 358.

Hyeon DY, et al. (2025) Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers. *Molecular cancer*, 24(1), 77.

Kerr TD, et al. (2025) HPV status impacts oncobacteria abundance and prognostic relevance in head and neck squamous cell carcinoma. *Oncogene*, 44(26), 2217.

Kumar R, et al. (2025) Race-related host and microbe transcriptomic signatures in triple-negative breast cancer. *NPJ breast cancer*, 11(1), 87.

Choi I, et al. (2025) Secretory IgA dysfunction underlies poor prognosis in *Fusobacterium*-infected colorectal cancer. *Gut microbes*, 17(1), 2528428.

Lin Y, et al. (2025) Dissecting the role of gut microbiota heterogeneity in the onset of chronic lung diseases. *AMB Express*, 15(1), 119.

Ou L, et al. (2024) *Helicobacter pylori* infection facilitates cell migration and potentially impact clinical outcomes in gastric cancer. *Heliyon*, 10(17), e37046.

Nikitina A, et al. (2024) Viral Transcript and Tumor Immune Microenvironment-Based Transcriptomic Profiling of HPV-Associated Head and Neck Squamous Cell Carcinoma Identifies Subtypes Associated with Prognosis. *Viruses*, 17(1).

Phumiphanjarphak W, et al. (2024) Entourage: all-in-one sequence analysis software for genome assembly, virus detection, virus discovery, and intrasample variation profiling. *BMC bioinformatics*, 25(1), 222.

Tian Q, et al. (2024) Application and Comparison of Machine Learning and Database-Based Methods in Taxonomic Classification of High-Throughput Sequencing Data. *Genome biology and evolution*, 16(5).

Xu W, et al. (2024) Elucidating the genotoxicity of *Fusobacterium nucleatum*-secreted mutagens in colorectal cancer carcinogenesis. *Gut pathogens*, 16(1), 50.

Taylor KD, et al. (2024) Metagenomic Study of the MESA: Detection of *Gemella Morbillorum* and Association With Coronary Heart Disease. *Journal of the American Heart Association*, 13(19), e035693.

Kim JH, et al. (2024) Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion. *Cancer research communications*, 4(6), 1467.

Robinson W, et al. (2024) Identification of intracellular bacteria from multiple single-cell RNA-seq platforms using CSI-Microbes. *Science advances*, 10(27), eadj7402.

Cornish AJ, et al. (2024) The genomic landscape of 2,023 colorectal cancers. *Nature*, 633(8028), 127.